FOOTNOTES
*Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in dry eye disease is not known.1,2,5
Your patient’s eyes deserve a change
Consider prescribing Xiidra, a first-in-class Rx therapy indicated for the treatment of the signs and symptoms of dry eye disease.1,6‡
‡Xiidra is an LFA-1 antagonist for the treatment of dry eye disease.1

Potential Lasting symptom relief that can start in as early as 2 weeks†
Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

Help Address the signs of dry eye disease
In 3 out of 4 studies, Xiidra showed notable improvements in signs (based on ICSS) of dry eye disease.1

Safety data in clinical trials1
The adverse reactions of Xiidra were studied across 5 clinical trials.§

access for your patients¶
Significantly broader coverage for your Medicare patients: Xiidra is now covered for nearly 3 out of 4 Medicare Part D patients (approximately 70% as of 7/1/22).7
Xiidra has comparable or better coverage to Restasis for 88% of commercially insured patients.8¶
¶Based on Commercial Formulary Access in National and Regional Accounts on July 12, 2022.
†The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). Effects on symptoms of dry eye disease: a larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease: at day 84, a larger reduction in ICSS favoring Xiidra was observed in 3 out of the 4 studies.1
§In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least 1 dose of lifitegrast (1287 of whom received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. One hundred-seventy patients were exposed to Xiidra for approximately 12 months. The most common adverse reactions (reported in 5-25% of patients) were instillation-site irritation, dysgeusia, and reduced visual acuity.1
¶Based on Commercial Formulary Access in National and Regional Accounts on January 18, 2022.